Skip to main content
Premium Trial:

Request an Annual Quote

Lumera Licenses Helix Biopharma Technology in Bid to Enter Protein Array Market

NEW YORK, Jan. 25 (GenomeWeb News) - Lumera said today that it has acquired the exclusive rights to protein surface chemistry from Helix Biopharma in order to further its development of a proteomic microarray.

 

Lumera said it will combine Helix Biopharma's Heterodimer Protein Technology with its own NanoCapture Array technology. The integrated technologies will allow Lumera to produce and capture proteins on a silicon surface while keeping the proteins fully functional, the company said.

 

Financial terms of the agreement were not provided.

 

The company said it has already produced prototype chips using the combined technologies, and carried out enzymatic, binding, and proteomic studies.

 

Lumera said it plans to begin shipping a product based on the technology later this year.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.